Aims: This study is aimed at evaluating the antidiabetic effects of thymoquinone (TQ) on streptozotocin (STZ)-induced diabetes in rats, and exploring the possible underlying mechanisms. Methods: Diabetes was induced in adult male Wistar rats by intraperitoneal injection of freshly prepared STZ (65 mg/kg). After disease induction, 42 rats were equally assigned to: controls, STZ-diabetic group, and STZ-diabetic group treated with oral TQ (35 mg/kg/day) for 5 weeks. Fasting blood glucose levels were determined weekly, and the animals were euthanized at day 38 post-STZ injection. Blood samples were assessed for glucose-insulin homeostasis parameters (plasma glucose, glycated hemoglobin, serum insulin, homeostatic model assessment of insulin resistance, and insulin sensitivity index) and lipid profile. Resected pancreases were subjected to histological examination and immunohistochemical or enzyme-linked immunosorbent assay assessment to determine the pancreatic expression of insulin sensitizing β-cells, anti-apoptotic protein “survivin,” apoptosis-inducer “caspase-3,” prototypic angiogenic factors (vascular endothelial growth factor [VEGF] and endothelial cluster of differentiation 31 [CD31]), pro- and anti-inflammatory cytokines (interleukin-1beta [IL-1β] and interleukin-10 [IL-10], respectively), thiobarbituric acid reactive substances (TBARS), total glutathione (GSH), and superoxide dismutase (SOD). The hepato-renal statuses were assessed biochemically and histologically. Results: Therapy with TQ markedly improved the integrity of pancreatic islets, glucose-insulin homeostasis-related parameters, lipid profile parameters, and hepato-renal functional and histomorphological statuses that collectively were severely deteriorated in untreated diabetic group. Mechanistically, TQ therapy efficiently increased insulin producing β-cells, upregulated survivin, VEGF, CD31, IL-10, GSH and SOD, and downregulated caspase-3, IL-1β, and TBARSs in the pancreatic tissues of STZ-diabetic rats. Conclusions: These findings prove the anti-diabetic potential of TQ and its efficacy in regenerating pancreatic β-cells and ameliorating pancreatic inflammation and oxidative stress, and highlight its novelty in repressing apoptosis of β-cells and enhancing islet revascularization in STZ-diabetic rats. Further studies are required to support these findings and realize their possible clinical significance.

Keywords:
Thymoquinone, Survivin, Caspase-3, Vascular endothelial growth factor, Cluster of differentiation 31, Interleukin-1beta, Interleukin-10, Rats, Diabetes
1.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-149.
2.
Zaccardi F, Webb DR, Yates T, Davies MJ: Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J 2016;92:63-69.
3.
Tanabe K, Amo-Shiinoki K, Hatanaka M, Tanizawa Y: Interorgan crosstalk contributing to β-cell dysfunction. J Diabetes Res 2017;2017:3605178.
4.
Tomita T: Apoptosis in pancreatic β-islet cells in type 2 diabetes. Bosn J Basic Med Sci 2016;16:162-179.
5.
Tomita T: Apoptosis of pancreatic β-cells in type 1 diabetes. Bosn J Basic Med Sci 2017, Epub ahead of print.
6.
Takamiya Y, Oikawa Y, Yamada T, Shimada A, Itoh H: Decrease in vascular endothelial growth factor expression area in islets may be associated with type 2 diabetes development. Diabetol Int 2012;3:202.
7.
Johansen JS, Harris AK, Rychly DJ, Ergul A: Oxidative stress and the use of antioxidants in diabetes linking basic science to clinical practice. Cardiovas Diabetol 2005;4:5.
8.
Tiganis T: Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharmacol Sci 2011;32:82-89.
9.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
10.
Ohkura T: Ipragliflozin: a novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015;6:136-144.
11.
Arnaud M, Bezin J, Bégaud B, Pariente A, Salvo F: Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France. Fundam Clin Pharmacol 2017, Epub ahead of print.
12.
Kaatabi H, Bamosa AO, Badar A, Al-Elq A, Abou-Hozaifa B, Lebda F, et al: Nigella sativa improves glycemic control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: placebo controlled participant blinded clinical trial. PLoS One 2015;10:e0113486.
13.
Darakhshan S, Bidmeshki Pour A, Hosseinzadeh Colagar A, Sisakhtnezhad S: Thymoquinone and its therapeutic potentials. Pharmacol Res 2015;95-96:138-158.
14.
Gholamnezhad Z, Havakhah S, Boskabady MH: Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol 2016;190:372-386.
15.
Abdelmeguid NE, Fakhoury R, Kamal SM, Al Wafai RJ: Effects of Nigella sativa and thymoquinone on biochemical and subcellular changes in pancreatic β-cells of streptozotocin-induced diabetic rats. J Diabetes 2010;2:256-266.
16.
Gray JP, Burgos DZ, Yuan T, Seeram N, Rebar R, Follmer R, et al: Thymoquinone, a bioactive component of Nigella sativa, normalizes insulin secretion from pancreatic β-cells under glucose overload via regulation of malonyl-CoA. Am J Physiol Endocrinol Metab 2016;310:E394-E404.
17.
Nader MA, el-Agamy DS, Suddek GM: Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. Arch Pharm Res 2010;33:637-643.
18.
Ozer EK, Goktas MT, Toker A, Pehlivan S, Bariskaner H, Ugurluoglu C, et al: Thymoquinone protects against the sepsis induced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ damage in rats. Pharmacol Rep 2017;69:683-690.
19.
Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA: Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2016;389:381-391.
20.
Atta MS, Almadaly EA, El-Far AH, Saleh RM, Assar DH, Al Jaouni SK, et al: Thymoquinone defeats diabetes-induced testicular damage in rats targeting antioxidant, inflammatory and aromatase expression. Int J Mol Sci 2017;18:pii:E919.
21.
Ahmad S, Beg ZH: Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem 2013;138:1116-1124.
22.
Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001;50:537-546.
23.
Lenzen S: The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008;51:216-226.
24.
Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, et al: Single dose streptozotocin- induced diabetes: considerations for study design in islet transplantation models. Lab Anim 2012;45:131-140.
25.
Vats V, Yadav SP, Grover JK: Ethanolic extract of Ocimum sanctum leaves partially attenuates streptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats. J Ethnopharmacol 2004;90:155-160.
26.
Rungseesantivanon S, Thengchaisri N, Ruangvejvorachai P, Patumraj S: Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-κB suppression. Diabetes Metab Syndr Obes 2010;3:421-429.
27.
Kensara OA, El-Shemi AG, Mohamed AM, Refaat B, Idris S, Ahmad J: Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats. Drug Des Devel Ther 2016;10:2239-2253.
28.
Sun Q, Nie S, Wang L, Yang F, Meng Z, Xiao H, et al: Factors that affect pancreatic islet cell autophagy in adult rats: evaluation of a calorie-restricted diet and a high-fat diet. PLoS One 2016;11:e0151104.
29.
Chen YC, Fueger PT, Wang Z: Depletion of PAK1 enhances ubiquitin-mediated survivin degradation in pancreatic β-cells. Islets 2013;5:22-28.
30.
Dohi T, Salz W, Costa M, Ariyan C, Basadonna GP, Altieri DC: Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep 2006;7:438-443.
31.
Jiang Y, Nishimura W, Devor-Henneman D, Kusewitt D, Wang H, Holloway MP, et al: Postnatal expansion of the pancreatic beta-cell mass is dependent on survivin. Diabetes 2008;57:2718-2727.
32.
Wu X, Zhang Q, Wang X, Zhu J, Xu K, Okada H, et al: Survivin is required for beta-cell mass expansion in the pancreatic duct-ligated mouse model. PLoS One 2012;7:e41976.
33.
Liadis N, Murakami K, Eweida M, Elford AR, Sheu L, Gaisano HY, et al: Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol Cell Biol 2005;25:3620-3629.
34.
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-1123.
35.
Abukhader MM: Thymoquinone in the clinical treatment of cancer: Fact or fiction? Pharmacogn Rev 2013;7:117-120.
36.
Chen L, Li B, Chen B, Shao Y, Luo Q, Shi X, et al: Thymoquinone alleviates the experimental diabetic peripheral neuropathy by modulation of inflammation. Sci Rep 2016;6:31656.
37.
Abd El-Ghany RM, Sharaf NM, Kassem LA, Mahran LG, Heikal OA: Thymoquinone triggers anti-apoptotic signaling targeting death ligand and apoptotic regulators in a model of hepatic ischemia reperfusion injury. Drug Discov Ther 2009;3:296-306.
38.
Sheikhbahaei F, Khazaei M, Rabzia A, Mansouri K, Ghanbari A: Protective effects of thymoquinone against methotrexate-induced germ cell apoptosis in male mice. Int J Fertil Steril 2016;9:541-547.
39.
Guida MS, Abd El-Aal A, Kafafy Y, Salama SF, Badr BM, Badr G: Thymoquinone rescues T lymphocytes from gamma irradiation-induced apoptosis and exhaustion by modulating pro-inflammatory cytokine levels and PD-1, Bax, and Bcl-2 signaling. Cell Physiol Biochem 2016;38:786-800.
40.
Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, et al: Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 2004;53:963-970.
41.
Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, et al: Pancreatic islet production of VEGF is essential for islet vascularization, revascularization, and function. Diabetes 2006;55:2974-2985.
42.
Gu H, Xia X, Chen Z, Liang H, Yan J, Xu F, et al: Insulin therapy improves islet functions by restoring pancreatic vasculature in high-fat diet-fed streptozotocin-diabetic rats. J Diabetes 2014;6:228-236.
43.
Chien CY, Yuan TA, Cho CH, Chang FP, Mao WY, Wu RR, et al: All-trans retinoic acid ameliorates glycemic control in diabetic mice via modulating pancreatic islet production of vascular endothelial growth factor-A. Biochem Biophys Res Commun 2016;477:874-880.
44.
Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T: Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008;29:334-350.
45.
Chen F, Zhou X, Lin Y, Jing C, Yang T, Ji Y, et al: Resveratrol prevents interleukin-1β-induced dysfunction of pancreatic β-cells. J Biomed Res 2010;24:381-388.
46.
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T: Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668.
47.
Zhang ZL, Shen SX, Lin B, Yu LY, Zhu LH, Wang WP, et al: Intramuscular injection of interleukin-10 plasmid DNA prevented autoimmune diabetes in mice. Acta Pharmacol Sin 2003;24:751-756.
48.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al: Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis 2014;64:510-533.
49.
Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-827.
50.
Ragheb A, Attia A, Eldin WS, Elbarbry F, Gazarin S, Shoker A: The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl 2009;20:741-752.
51.
Omran OM: Effects of thymoquinone on STZ-induced diabetic nephropathy: an immunohistochemical study. Ultrastruct Pathol 2014;38:26-33.
52.
Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-159.
53.
Okuyama H, Langsjoen PH, Ohara N, Hashimoto Y, Hamazaki T, Yoshida S, et al: Medicines and vegetable oils as hidden causes of cardiovascular disease and diabetes. Pharmacology 2016;98:134-170.
54.
Aiman U, Najmi A, Khan RA: Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother 2014;5:181-185.
55.
Kei A, Rizos EC, Elisaf M: Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis 2015;6:246-251.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.